Australia markets closed

Neurocrine Biosciences, Inc. (NBIX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
132.00-0.54 (-0.41%)
At close: 04:00PM EDT
132.00 0.00 (0.00%)
After hours: 04:58PM EDT
Show:
Income statement
Cash flow
Annual

Balance sheet

All numbers in thousands
Breakdown
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Assets
Current assets
Cash
Cash and cash equivalents
251,100
262,900
340,800
187,100
Other short-term investments
780,500
726,400
370,500
613,900
Total cash
1,031,600
989,300
711,300
801,000
Net receivables
439,300
350,000
185,500
157,100
Inventory
38,300
35,100
30,500
28,000
Other current assets
97,800
79,100
45,500
30,100
Total current assets
1,607,000
1,453,500
972,800
1,016,200
Non-current assets
Property, plant and equipment
Gross property, plant and equipment
430,300
211,900
207,700
169,100
Accumulated depreciation
-83,000
-66,300
-51,900
-41,700
Net property, plant and equipment
347,300
145,600
155,800
127,400
Equity and other investments
849,400
401,500
624,400
265,300
Intangible assets
35,500
37,200
-
-
Other long-term assets
49,600
25,000
4,400
6,400
Total non-current assets
1,644,400
915,200
1,099,700
718,500
Total assets
3,251,400
2,368,700
2,072,500
1,734,700
Liabilities and stockholders' equity
Liabilities
Current liabilities
Current debt
170,100
169,400
-
-
Accounts payable
108,900
67,300
51,500
39,400
Taxes payable
24,400
9,000
-
-
Accrued liabilities
176,200
139,400
111,600
94,700
Other current liabilities
35,900
20,700
20,000
17,800
Total current liabilities
654,800
537,700
245,800
186,500
Non-current liabilities
Long-term debt
-
-
335,100
317,900
Other long-term liabilities
10,300
9,900
12,300
9,700
Total non-current liabilities
364,600
123,200
452,700
422,000
Total liabilities
1,019,400
660,900
698,500
608,500
Stockholders' equity
Common stock
100
100
100
100
Retained earnings
-157,100
-406,800
-635,800
-725,400
Accumulated other comprehensive income
7,000
-7,900
-1,700
1,800
Total stockholders' equity
2,232,000
1,707,800
1,374,000
1,126,200
Total liabilities and stockholders' equity
3,251,400
2,368,700
2,072,500
1,734,700